Background: Genome-wide association studies (GWAS) identify associations of individual single-nucleotide polymorphisms (SNPs) with cancer risk but usually only explain a fraction of the inherited variability. Pathway analysis of genetic variants is a powerful tool to identify networks of susceptibility genes. Methods: We conducted a large agnostic pathway-based meta-analysis of GWAS data using the summary-based adaptive rank truncated product method to identify gene sets and pathways associated with pancreatic ductal adenocarcinoma (PDAC) in 9040 cases and 12 496 controls. We performed expression quantitative trait loci (eQTL) analysis and functional annotation of the top SNPs in genes contributing to the top associated pathways and gene sets. All statistical tests were two-sided. Results: We identified 14 pathways and gene sets associated with PDAC at a false discovery rate of less than 0.05. After Bonferroni correction (P 1.3 Â 10
Although pancreatic ductal adenocarcinoma (PDAC) only accounts for about 3% of all cancer, it's the third leading cause of cancer-related death in the United States and its incidence is increasing (1) . PDAC is among the most fatal cancers worldwide, and there are few established preventable risk factors beyond cigarette smoking, diabetes, overweight, and obesity (2) . There are no effective screening methods for the detection of PDAC; therefore, most people are diagnosed with advanced disease, which contributes to the dismal 5-year survival of 8.2% (1) . Understanding the biology underlying the development of PDAC could be useful in developing new treatments or to identify those at high risk for surveillance or targeted intervention
Over the past decade, genome-wide association studies (GWAS) have identified 20 genomic loci associated with PDAC susceptibility in European populations (3) (4) (5) (6) (7) (8) . Although GWAS have provided valuable insights into the genetic basis of PDAC, the susceptibility loci identified do not fully account for the genetic heritability of this disease because of the relative small effect sizes associated with individual single-nucleotide polymorphisms (SNPs) and the multiple testing correction required for GWAS. Thus, many important susceptibility genes may well remain unidentified. Pathway-based analyses applied to GWAS have the potential to detect associations that may be overlooked by standard single-marker approaches and can be a complementary method to identify groups of genes or biological pathways enriched with disease-associated SNPs (9, 10) . Pathway analysis, which jointly considers multiple variants in interacting genes and multiple genes in a pathway, may also allow more meaningful biologic interpretation.
We previously conducted a pathway analysis of genes in 23 candidate biological pathways hypothesized a priori to be associated with PDAC (10) . PDAC-associated pathways identified included pancreatic development, Helicobacter pylori lacto/neolacto, hedgehog, Th1/Th2 immune response, and apoptosis. This study was limited by the number of participants and pathways/genes examined, suggesting a larger study with a more comprehensive approach may detect associations not previously considered in PDAC. Consequently, in the present study, we included 3795 human canonical pathways and gene sets from the Broad Institute Molecular Signatures Database (MSigDB) using an agnostic data-driven approach to identify genes and pathways associated with PDAC susceptibility within the Pancreatic Cancer Cohort Consortium (PanScan I, II, III) and the Pancreatic Cancer Case Control Consortium (PanC4) GWAS.
Methods

Study Population and Data
Methods for GWAS studies have previously been described (3) (4) (5) (6) 8) . The study sample included 9040 primary pancreatic adenocarcinoma cases (ICD-O-3 code C250-C259) and 12 496 control participants of European genetic ancestry from summary data from previous PanScan and PanC4 GWAS (3) (4) (5) (6) (7) (8) . All participants gave informed consent and all studies were approved by the institutional review board of each participating institution and the National Cancer Institute.
Pathway and Gene Set-Based Analyses Using GWAS Summary Data
A total of 3795 human-derived gene sets and canonical pathways from The Broad Institute MSigDB v5.0 database (http:// software.broadinstitute.org/gsea/msigdb/collections.jsp) were used for the analysis. Canonical pathways (n ¼ 1369) included BioCarta; Hallmark; Kyoto Encyclopedia of Genes and Genomes (KEGG); Pathway Interaction Database (National Cancer Institute and Nature Publishing Group); Reactome; Signaling Gateway (SIG); Signaling Transduction KE, and Sigma Aldrich. Gene sets (n ¼ 2426) included studies with expression signatures (or changes in expression levels) following genetic and chemical perturbations. Gene sets represented genes induced (upregulated) and repressed (downregulated) by the perturbation. The size of gene sets and pathways ranged from 2 to 1668 genes. SNPs were mapped within a genomic region encompassing 20 kb upstream and downstream of each gene.
We conducted a meta-analysis using summary statistics from the four GWAS using an inverse variance fixed-effects model (k ¼ 1.07). An initial analysis on all of the SNPs resulted in 112 pathways or genes sets associated with PDAC below the Bonferroni statistical significance threshold (P ¼ 1.3 Â 10 À5 , 0.05/3795) (data not shown). Most were driven by one or more previously identified GWAS variants, not a pathway association. Therefore, to identify pathway or gene set associations that were jointly driven by novel SNPs, we excluded previously published GWAS PDAC cancer risk signals at 1q32.1 (NR5A2), 2p13.3 (ETAA1), 3q29 (TP63), 5p15.33 (CLPTM1L-TERT), 7p13 (SUGCT), chr8q24.21 (MYC), 7q32.2 (LINC-PINT), 9q34.2 (ABO), 13q12.2 (PDX1), 13q22.1 (KLF5/KLF12), 16q23.1 (BCAR1), 17q25.1 (LINC00673), and 22q12.1 (ZNRF3) (3-7) and SNPs with metaanalysis at GWAS threshold P value less than 5 Â 10 À8 (signal at 7p12 [TNS3]) from our analysis plus corresponding genomic regions within roughly 500 kb to eliminate association signals that could be caused by linkage disequilibrium (LD) (11) . In total, 207 genes were excluded using these criteria. We excluded SNPs with minor allele frequency less than 1% and applied LD filtering to highly correlated SNP pairs (r 2 > .81).
We conducted gene and pathway meta-analyses using the summary-based adaptive rank truncated product (sARTP) method, which combines SNP-level associations across SNPs in a gene or a pathway (11) . The signals from up to two of the most associated SNPs in a gene were accumulated. The sARTP method adjusted for the size of genes and pathways (ie, number of SNPs in a gene and number of genes in a pathway) through a resampling procedure to control for false positives. The P values of gene-and pathway-level associations were estimated from the resampled null distribution generated from 100 million resampling steps. A panel of 503 European subjects (population codes: CEU, TSI, FIN, GBR, IBS) in the 1000 Genomes Project (phase 3, v5, 2013/05/024) was used in sARTP to estimate the LDs between SNPs. To eliminate the impact of population stratification, the genomic control inflation factor was adjusted by using ffiffiffiffiffiffiffiffiffi ffi 1:07 p to rescale the standard error of the estimated log odds ratio at each SNP. We considered a false discovery rate (FDR) adjusted pathway-level P value less than or equal to .05 to be statistically significant; however we discuss pathways and gene sets below the Bonferroni adjusted a-level (P ¼ 1.3 Â 10
À5
[.05/3795]). All statistical tests are two-sided.
Functional Annotation and eQTL Analysis
Experimental data from ENCODE (12) custom tracks on the UCSC Genome Browser and Roadmap (13) and information from Ensembl (14) , RegulomeDB v1.1 (15) , LDlink (16) , and HaploReg v4.1 (17) were used to evaluate the regulatory relevance of SNPs (and SNPs in LD) of interest in pancreatic and other tissue types. eQTL was performed to evaluate effects on expression and tissue specificity for the most statistically significant SNPs using publicly available data from the National Institutes of Health Genotype-Tissue Expression (GTEx) v7 (18) in pancreas tissue samples (n ¼ 220). Potential eQTLs from this analysis (P < .05) were then taken forward for further analysis. eQTL analysis of selected SNPs (n ¼ 53 SNPs mapped to 69 genes) (identified by one or more features including SNP P value, RegulomeDB score, and GTEx eQTL result) were validated using data from histologically normal pancreas tissue samples (n ¼ 95) from the Laboratory of Translational Genetics (LTG) as previously described (19) . P values for SNP-gene tests were adjusted for multiple comparisons using Bonferroni correction (P ¼ .05/69 ¼ 7.25 Â 10
À4
).
Results
Pathway and Gene Set-Based Analyses
Fourteen pathways and gene sets were associated with PDAC (at FDR < 0.05), of which two gene sets and three pathways remaining statistically significant after the Bonferroni correction (Table 1) ; including maturity-onset diabetes of the young (MODY) (P ¼ 5.10 Â 10 À7 ), regulation of beta-cell development
), role of EGF receptor transactivation by G protein-coupled receptors (GPCRs) in cardiac hypertrophy (P ¼ 3.79 Â 10 À6 ) and Pujana ATM PCC network (P ¼ 1.25 Â 10 À5 ).
The MODY pathway that contained 1448 SNPs across 23 genes was the most statistically significant pathway. The genes with the strongest association in this pathway and the corresponding top SNP(s) were HNF1A (rs1169296, rs2244608), HNF1B (rs12951345, rs7223387), HNF4A (rs1853150), HNF4G (rs1913641, rs2943547), and PAX4 (rs118117270, rs62483175) ( Table 1 , available online). This suggests an overlap in signals between these two pathways; however, the PAX4 gene was only present in the MODY pathway.
The role of EGF receptor transactivation by GPCRs in the cardiac hypertrophy pathway included 2133 SNPs across 17 genes. EDNRA (rs35232409, rs6537481) and AGT (rs1326889) were the top genes (P ¼ 5.47 Â 10 À6 and 9.21 Â 10
À5
, respectively) (Figure 2, Supplementary Table 2, available online).
The Nikolsky breast cancer 17q11-q21 amplicon gene set included 131 genes (3320 SNPs) and the association was driven by 36 genes (Figure 3 , Supplementary Table 3, available online). The top five genes were PGAP3, PNMT, TCAP, ERBB2, and STARD3 (gene P values < 3.00 Â 10 À5 ), all corresponding to two SNPs,
) and rs3764351 (P ¼ 1.27 Â 10
) . Additional genes contributing to this pathway included HNF1B (rs12951345, rs7223387), IGFBP4 (rs7225411, rs76592685), TNS4 (rs7225411, rs113557550), MED24/THRA (rs8078692, rs113520394), and FBXL20 (rs62074998, rs12453796) (gene P values < .001). The SNPs selected by the sARTP method in the top 36 genes (gene P < .04) were not all in high LD with each other (r 2 range ¼ 0.002-0.6), suggesting multiple signals in this region may be associated with PDAC. In the Pujana ATM PCC network, 67 of 1350 genes were selected by sARTP as contributing the most to the PDAC association ( Figure 4 , Supplementary Table 4 , available online). The three top genes (gene P < 7.55 Â 10 À5 ) were SMC2 (rs7859034),
PNMT (rs876493, rs3764351), and HNF1B (rs12951345, rs7223387).
Other notable genes (gene P < 0.01) in this gene set included HNF1A (rs1169291, rs1169297), GRP (rs57791062), ACTR2 (rs2160263, rs7579797), THRA (rs8078692, rs113520394), HNF4G (rs1913641, rs2943547), HEXA (rs11636684, rs201611588), TAB1 (rs34825318), MED1 (rs113897737, rs7212868), and CASP7 (rs3124737). The full list of genes and sARTP-selected SNPs that contributed to the Bonferroni statistically significant pathways/ gene sets are summarized in Supplementary Table 5 (available  online) . Some of our findings were supported by recent consortia efforts in conducting GWAS meta-analysis on PDAC risk (8) . By combing the four GWAS used in our study with an additional replication data of selected SNPs (2737 cases; 4752 controls), four new GWAS signals were identified (8) . As our analysis was conducted before this, we further excluded these GWAS signal regions at 1p36.33 (NOC2L), 8q21.11 (HNF4G), 17q12 (HNF1B), and 18q21.32 (GRP) (8) . Eight of the 14 FDR statistically significant pathways or gene sets included these regions and were attenuated after their exclusion (Supplementary Table 6 , available online, P values < .01); however, the Nikolsky breast cancer chr17q11-q21 amplicon gene set remained statistically significant (P ¼ 5.71 Â 10
À6
) after Bonferroni correction. The ATM PCC network, MODY, and regulation of beta-cell development had P values of 3.59 Â 10
À4
, 5.49 Â 10
, and .001, respectively. The other six pathways/gene sets did not include these regions and were unaffected.
eQTL and Functional Annotation
We present the functional annotations and eQTL results from GTEx tissues and replication in an independent eQTL histologically normal pancreas dataset (LTG) (19) for the five Bonferroni statistically significant pathways and gene sets (Table 2 and  Supplementary Tables 7 and 8 , available online). Top SNP rs876493-A was present in both the Nikolsky breast cancer chr17q11-q21 amplicon and Pujana ATM network gene sets, and was associated with lower PGAP3 expression in normal pancreatic tissue in GTEx (P¼3.90 Â 10
À7
, b ¼ À.24) and in the LTG (P¼1.16 Â 10
À5
, b ¼ À. 43 ). In addition, we identified and validated three additional SNPs-rs3764351-A, rs4795393-T, and rs12453507-G in LD with rs876493-A-that also act as eQTLs for PGAP3 in both datasets (Table 2 ). These SNPs were also associated with lower PGAP3 expression in other tissues (Supplementary Table 7 , available online). The LD between these four SNPs on chr17 may indicate the same signal is contributing to the associations.
In the Pujana ATM PCC network, we observed that the risk allele rs3124737-G (CASP7) was associated with higher expression of the CASP7 gene in normal pancreatic tissue using GTEx (P ¼ 2.50 Â 10 À8 ; b ¼ .48) and LTG (P ¼ 0.02; b ¼ .28) ( Table 2) . We also observed this eQTL effect in multiple tissues from GTEx including thyroid, subcutaneous adipose, and whole blood (Supplementary Table 7 , available online). The two SNPs (rs876493-A [PGAP3] and rs3124737-G [CASP7]) supported by eQTL were not identified or in LD with signals from the recent GWAS meta-analysis and remained statistically significant after exclusion of the new GWAS regions (8) .
Discussion
We identified 14 pathways and gene sets associated with PDAC, five of which met the Bonferroni correction for multiple , HNF1A, ACTR2, GRP, THRA,  HNF4G, TAB1, HEXA, MED1, HIPK3, GHRH, CASP7,  MED6, TPP2, KHDRBS2, FCHSD2, OIP5, CSF3,  PHOX2B, GRIA1, HNRNPL, HNRNPAB, PMS2P1,  PFKFB4, GSR, AOC2, MAPK8, BCL2L11, E2F4, PFDN6,  NPHP1, PCF11, LDHB, BTF3, SIKE1, PAX4, NMI,  TMEM123, ANGEL1, RPL19, PIBF1, POP4, PSMD3,   USP19, GPR3, SP2, CD47, RPL30, KIF20B, BRCA1,  NSL1, SNRNP27, BAZ1A, TAF5, ITGBL1, NR2C1,  ATXN3, TACR3, TELO2, TRA2B, NAE1, FBL, USP4,  CDC123, FAM53B, CR1, PDAP1, CD52, TNFAIP8,  F2RL3, ATP5G2, CAMK4, RHOH, PPIP5K2, CHAF1B,  XRCC2, KIAA0922, CDH8, GPR171, RAB30, SGPL1,  PPM1A, ARID1A, PAICS, DRD1, MR1, SPI1, CYP2C18,  TTYH2, *Pathway-based meta-analysis used the sARTP method, which combines SNP-level association statistics across SNPs in a gene or a pathway. Each statistically significant contributing gene includes up to two SNPs. The sARTP method adjusts for the size of genes (ie, number of SNPs in a gene) and the size of pathways (ie, number of genes in a pathway) through a resampling procedure. EGF ¼ epidermal growth factor; GPCR ¼ G protein-coupled receptor;
HCP ¼ high CpG-density promoters; PGR ¼ progesterone; sARTP ¼ summary-based adaptive rank truncated product; SNP ¼ single-nucleotide polymorphism. †The pathway-level association P values were estimated from the resampled null distribution through up to 100 million resampling steps as described in the Methods section. All statistical tests were two-sided. ‡Statistically significant pathways/gene sets at Bonferroni-adjusted a-level
testing. The strongest pathways associated with PDAC included genes involved in susceptibility to MODY, pancreatic beta-cell development, cardiac hypertrophy, breast cancer chr17q11-q21 amplicon, and a network of genes correlated with ATM gene expression. Our PDAC associations for the MODY and pancreatic beta-cell development pathways add evidence and reinforce previous epidemiologic findings based on candidate genes, pleiotropy, and GWAS approaches (5, 7, 8, 10, (20) (21) (22) . The genes in these pathways are important components for transcriptional networks governing embryonic pancreatic development, differentiation, and pancreatic homeostasis (23, 24) . MODY accounts for 2% of all diabetes and is caused by genetic mutations that affect islet beta-cell function (25) . We found no evidence that the variants linked to the genes in these pathways act as eQTLs in normal adult pancreas tissues. However, functional annotation showed that rs2244608-G (HNF1A) maps to an active transcription start site in normal ) were selected by sARTP as contributing the most to the pathway-PDAC association. All statistical tests were two-sided. PDAC ¼ pancreatic ductal adenocarcinoma; EGF ¼ epidermal growth factor; GPCRs ¼ G protein-coupled receptors; sARTP ¼ summary-based adaptive rank truncated product.
pancreas and islet cell tissue. PAX4 identified in the MODY pathway has not previously been implicated in PDAC. PAX4 is essential for islet development and adult beta-cell survival and expansion (24) . Mutations and germline polymorphisms in PAX4 are associated with type 1 and type 2 diabetes and MODY type 9 (25) . The EDNRA (endothelin receptor type A) and AGT (angiotensinogen) genes were the top genes in the EGF cardiac pathway, a pathway which has not previously been implicated in PDAC susceptibility. This pathway describes cardiac hypertrophy (thickening of the heart muscle) through activation of the EGFR (epidermal growth factor receptor) by GPCRs, which transactivate EGFR in numerous cell types and cancers, resulting in downstream activation of biological processes (26, 27) . EDNRA is a GPCR for endothelin (ET-1), a potent vasoconstrictor that may play a role in obesity and insulin resistance (28) . Overexpression of EDNRA has been associated with many cancers (29) (30) (31) (32) . Inhibition of EDNRA demonstrated antiangiogenic and antiproliferative activity in pancreatic cancer cell lines (33) . AGT encodes an angiotensin precursor, a potent vasoconstrictor involved in blood pressure regulation and a potential cell growth . Genes associated with PDAC in the Nikolsky breast cancer chr17q11-q21 amplicon gene set (P ¼ 2.00 Â 10 À6 ). A total of 36 genes (red circles, P < .04) were selected by sARTP as contributing the most to the gene set-PDAC association. All statistical tests were two-sided. PDAC ¼ pancreatic ductal adenocarcinoma; sARTP ¼ summary-based adaptive rank truncated product. ACTR2   SIKE1  GPR3   BCL2L11  NPHP1  NMI  SNRNP27   PFKFB4  USP19  CD47  TRA2B  USP4   PHOX2B   TACR3   GRIA1  HNRNPAB  BTF3   KHDRBS2   PFDN6   PMS2P1   PAX4   HNF4G   SMC2   CASP7   MAPK8  KIF20B  TAF5  FAM53B  CDC123   HIPK3   FCHSD2   TMEM123  PCF11   HNF1A   LDHB   NR2C1   MED6   ANGEL1  BAZ1A  ATXN3   TPP2   PIBF1  ITGBL1   HEXA   OIP5   E2F4   NAE1  TELO2   PNMT   HNF1B   THRA   MED1   CSF3   AOC2  RPL19  PSMD3  SP2  BRCA1   GRP   HNRNPL   POP4  FBL   GHRH   TAB1 -10log (P-value) Chromosome Figure 4 . Genes associated with PDAC in the Pujana ATM Pearson correlation coefficient (PCC) network gene set (P ¼ 1.25 Â 10 À5 ). A total of 67 genes (red circles, P < .02)
were selected by sARTP as contributing the most to the gene set-PDAC association. All statistical tests were two-sided. PDAC ¼ pancreatic ductal adenocarcinoma; sARTP ¼ summary-based adaptive rank truncated product.
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stimulator (34, 35) . Variant rs1326889 in AGT (SNP P ¼ 4.21 Â 10 À7 ) is associated with renal cell carcinoma, with stronger associations observed for overweight/obese or hypertensive participants (34) . The Nikolsky breast cancer chr17q11-q21 amplicon gene set represents genes that exhibit copy number alterations in 191 breast carcinomas (36) . The strongest associated SNP rs876493 (P ¼ 1.27 Â 10
À6
) and three additional correlated SNPs (r 2 range ¼ .3-.6), rs3764351, rs4795393, and rs12453507, were associated with decreased PGAP3 (post-GPI attachment to proteins 3) expression in both the GTEx and LTG pancreas tissue datasets and all four variants may represent the same signal (Table 2) . PGAP3, also known as PERLD1, is an oncogene in breast and gastric cancer, and is frequently coamplified with ERBB2 and CDK12 (37). Cosilencing of STARD3, GRB7, PSMD3, and PGAP3 together with ERBB2 led to an additive inhibition of cell viability and apoptosis in vitro (38) . The SNPs rs876493 and rs3764351 were also present in the Pujana ATM PCC network gene set. Our observed PDAC association for this breast cancer-derived gene set may suggest common genetic susceptibility for both cancers. The Pujana ATM PCC network gene set is based on gene expression integrated with functional genomic and proteomic data from human tissues and cell lines to classify networks associated with ATM (39). Numerous genes across multiple chromosomes contributed to the statistical significance of this gene set with PDAC, including but not limited to the MODY genes HNF1A, HNF1B, HNF4G, and PAX4. The ATM protein is a serine/threonine kinase involved in repair of DNA double-strand breaks (40) . Mutations in ATM are responsible for ataxia telangiectasia (40) . Germline mutations in ATM are known to be associated with 2%-3% of familial PDAC (41) (42) (43) and have recently been found in a case series of sporadic PDAC patients (44) . Our analysis identified rs7859034 (SMC2) (SNP P ¼ 3.07 Â 10 À7 ) as top signal in this gene set. SMC2 is a central component of the condensin complex required for converting interphase chromatin into mitotic-like condense chromosomes. SMC2 in cooperation with MYCN can transcriptionally regulate DNA damage response genes (45) . In this gene set, we additionally identified eQTL and functional annotation evidence for variants in the CASP7 gene (rs3124737, SNP P ¼ 3.29 Â 10 À5 ) in pancreas tissue. CASP7 is critical in apoptosis induction, acting as a candidate for susceptibility to insulin-dependent diabetes; inactivating mutations in CASP7 have been reported to contribute to the pathogenesis of some human solid cancers (46) . This gene set represents a biologic network not previously considered for sporadic PDAC that should be further researched and could have clinical application for classifying those at high risk. Four of the five Bonferroni statistically significant pathways or gene sets that we observed contained recently published GWAS signal regions (8) . When we excluded these regions, the Nikolsky chr17q11-q21 gene set remained Bonferroni statistically significant and the others had P values less than 0.001. Although we do not have a replication study for our analysis, the replication of the four SNPS in these regions in the meta-analysis GWAS study (8) adds to the validity of our pathway findings. Klein et al. (8) also identified four suggestive variants-rs6537481 (EDNRA), rs2417487 (SMC2), rs1182933 (HNF1A), and rs6073450 (HNF4A)-that did not reach genome-wide statistical significance; however, they were in LD with signals (or the same SNP [EDNRA]) that contributed to the biologically relevant pathways and gene sets of multiple smaller association signals observed in our study.
Strengths of our study are its large sample size for PDAC and agnostic pathway and gene set-based statistical approach using GWAS data. Combined with a sophisticated statistical method, sARTP maximized our ability to detect genetic associations that would not be discovered by the single-marker analysis conducted in conventional GWAS. The sARTP method also uses GWAS summary data, which facilitates consortia collaboration in sharing data for large-scale pathway analyses. We excluded reported GWAS SNPs, signals with a P-value threshold less than 5 Â 10
À8
and regions within roughly 500 kb to identify genetic contributions to PDAC susceptibility beyond the traditional GWAS threshold. The strongest contributing genes and selected SNPs observed within the statistically significant pathways and gene sets in our study may be identified in future GWAS with larger sample sizes.
Limitations of our study include the LD filtering threshold (r 2 > .81) used to exclude highly correlated SNPs, meaning potential variants in LD (r 2 < .81) could be selected for a gene that represents one signal. However, the sARTP method identifies SNPs and genes contributing the most to the overall pathway associations in a data-driven manner that may help with biologically meaningful result interpretation and has proven to be a powerful and effective strategy to analyze pathways (11) . An additional limitation may be the distance (kb) used to map SNPs to genes. Although, there is no agreed exact distance to assign SNPs to their relevant genes (47), we know that some genetic variants can affect RNA expression through cis or trans mechanisms (48) . In our study, we mapped SNPs 20 kb upstream and downstream of each gene to identify candidate SNPs that may play a regulatory role in gene expression. We and others have previously used this distance in annotating SNPs/genes in pathway analysis (11) , as studies have shown functional variants are located approximately 16-20 kb within transcription start sites (47) (48) (49) . Ultimately, approaches using causal SNPs based on chromatin interactions, cis-or trans-eQTL functional data for assigning SNPs to genes, will increase the precision of the associations and understanding of the biology beyond the functional annotations we performed using publicly available data and eQTL analyses in two normal pancreas tissue independent datasets.
In conclusion, translating GWAS data into biologically relevant pathways and gene sets expands our knowledge of the potential mechanisms underlying PDAC carcinogenesis, as well as providing evidence for the future development of clinically relevant multigenic predictors for identifying individuals at high risk. Further population, clinical, and laboratory research is needed to confirm our findings. Strategies to accelerate functional biological follow-up may include replication, fine mapping, experimental studies such as whole transcriptomic sequencing, reporter assays, and DNA methylation/epigenetic regulations on gene expression (50) to fully understand the biology and functional nature of the loci contributing to the pathways and gene sets associated with PDAC. 
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